SM: Keep an eye on shares of Amylin Pharmaceuticals and Eli Lilly today. The companies said late yesterday that the Food and Drug Administration has requested more information on Bydureon, the once-weekly version of diabetes drug Byetta. The FDA wanted the companies to further study the impact of the drug on heart rate. The drug uses Alkermes technology as well. The companies said they anticipate responding to the FDA's request by late 2011, after which the drug will face a six-month review period. For MarketNewsVideo.com, I'm Sayoko Murase.
标题
FDA Requests More Bydureon Info (MNV)
视频介绍
Market News Video - October 20, 2010
The FDA has requested more information on Bydureon from Eli Lilly and Amylin Pharmaceuticals.
